241 related articles for article (PubMed ID: 25663282)
1. Modifications of sequential designs in bioequivalence trials.
Zheng C; Zhao L; Wang J
Pharm Stat; 2015; 14(3):180-8. PubMed ID: 25663282
[TBL] [Abstract][Full Text] [Related]
2. Testing bioequivalence for multiple formulations with power and sample size calculations.
Zheng C; Wang J; Zhao L
Pharm Stat; 2012; 11(4):334-41. PubMed ID: 22692852
[TBL] [Abstract][Full Text] [Related]
3. Blinded sample size re-estimation in crossover bioequivalence trials.
Golkowski D; Friede T; Kieser M
Pharm Stat; 2014; 13(3):157-62. PubMed ID: 24715672
[TBL] [Abstract][Full Text] [Related]
4. Two-stage designs in bioequivalence trials.
Schütz H
Eur J Clin Pharmacol; 2015 Mar; 71(3):271-81. PubMed ID: 25604509
[TBL] [Abstract][Full Text] [Related]
5. Optimal adaptive sequential designs for crossover bioequivalence studies.
Xu J; Audet C; DiLiberti CE; Hauck WW; Montague TH; Parr AF; Potvin D; Schuirmann DJ
Pharm Stat; 2016; 15(1):15-27. PubMed ID: 26538182
[TBL] [Abstract][Full Text] [Related]
6. The role of the upper sample size limit in two-stage bioequivalence designs.
Karalis V
Int J Pharm; 2013 Nov; 456(1):87-94. PubMed ID: 23954235
[TBL] [Abstract][Full Text] [Related]
7. Two-stage designs for cross-over bioequivalence trials.
Kieser M; Rauch G
Stat Med; 2015 Jul; 34(16):2403-16. PubMed ID: 25809815
[TBL] [Abstract][Full Text] [Related]
8. Futility rules in bioequivalence trials with sequential designs.
Fuglsang A
AAPS J; 2014 Jan; 16(1):79-82. PubMed ID: 24218038
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of inferential procedures for adaptive clinical trial designs with pre-specified rules for modifying the sample size.
Levin GP; Emerson SC; Emerson SS
Biometrics; 2014 Sep; 70(3):556-67. PubMed ID: 24766094
[TBL] [Abstract][Full Text] [Related]
10. Information-based sample size re-estimation in group sequential design for longitudinal trials.
Zhou J; Adewale A; Shentu Y; Liu J; Anderson K
Stat Med; 2014 Sep; 33(22):3801-14. PubMed ID: 24797715
[TBL] [Abstract][Full Text] [Related]
11. Statistical methodology for highly variable compounds: A novel design approach for the ofatumumab Phase 2 bioequivalence study.
Jones B; Li B; Bagger M; Goodyear A; Ludwig I
Pharm Stat; 2022 Nov; 21(6):1357-1365. PubMed ID: 35604539
[TBL] [Abstract][Full Text] [Related]
12. A practical comparison of group-sequential and adaptive designs.
Kelly PJ; Sooriyarachchi MR; Stallard N; Todd S
J Biopharm Stat; 2005; 15(4):719-38. PubMed ID: 16022175
[TBL] [Abstract][Full Text] [Related]
13. Sample size re-estimation in group-sequential response-adaptive clinical trials.
Morgan CC
Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
[TBL] [Abstract][Full Text] [Related]
14. Operating characteristics of sample size re-estimation with futility stopping based on conditional power.
Lachin JM
Stat Med; 2006 Oct; 25(19):3348-65. PubMed ID: 16345019
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.
Karalis V; Symillides M; Macheras P
Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039
[TBL] [Abstract][Full Text] [Related]
16. A modified large sample approach in the assessment of population bioequivalence.
Quiroz J; Ting N; Wei GC; Burdick RK
J Biopharm Stat; 2000 Nov; 10(4):527-44. PubMed ID: 11104391
[TBL] [Abstract][Full Text] [Related]
17. Increasing the sample size when the unblinded interim result is promising.
Chen YH; DeMets DL; Lan KK
Stat Med; 2004 Apr; 23(7):1023-38. PubMed ID: 15057876
[TBL] [Abstract][Full Text] [Related]
18. Controlling type 1 error rate for sequential, bioequivalence studies with crossover designs.
Rasmussen HE; Ma R; Wang JJ
Pharm Stat; 2019 Jan; 18(1):96-105. PubMed ID: 30370634
[TBL] [Abstract][Full Text] [Related]
19. Group sequential, sample size re-estimation and two-stage adaptive designs in clinical trials: a comparison.
Shih WJ
Stat Med; 2006 Mar; 25(6):933-41. PubMed ID: 16220505
[No Abstract] [Full Text] [Related]
20. Two-stage designs versus European scaled average designs in bioequivalence studies for highly variable drugs: Which to choose?
Molins E; Cobo E; Ocaña J
Stat Med; 2017 Dec; 36(30):4777-4788. PubMed ID: 28853164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
